The Unit Economics of Disease Burden

How delayed diagnosis, patient complexity, and evidence gaps generate healthcare costs before reimbursement begins

Healthcare costs are often measured after treatment begins, but much of the economic burden develops long before patients receive the right intervention. Delayed diagnosis, fragmented care pathways, ineffective therapies, and patient complexity all contribute to healthcare utilization that is frequently overlooked in conventional evidence strategies.

In The Unit Economics of Disease Burden, Rubix LS explores why disease burden should be viewed as more than an epidemiological measure. The white paper examines how patient context, diagnostic pathways, and upstream evidence can provide a more complete understanding of healthcare costs and support stronger HEOR, real-world evidence, market access, and commercial decision-making.

Download White Paper